Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

• Main Authors: Molina J., Cahn P., Grinsztejn B., Lazzarin A., Mills A., Saag M., Supparatpinyo K., Walmsley S., Crauwels H., Rimsky L., Vanveggel S., Boven K.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79960381844&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/43029
• Institution: Chiang Mai University

Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non-nucleoside reverse transcriptase inhibitor, has shown similar antiviral efficacy to efavirenz in a phase 2b trial w...